Bharat Biotech's Covaxin Effective Against Coronavirus Variant Discovered In UK: ICMR Study

Hyderabad-based Bharat Biotech's Covid-19 vaccine, Covaxin, has equivalent immunogenicity against the Coronavirus variant discovered in the United Kingdom, a study by the Indian Council of Medical Research has found.

"A comparable neutralization activity of the vaccinated individuals sera showed against UK-variant and the heterologous strain with similar efficiency dispel the uncertainty of possible neutralization escape," the ICMR study document published in pre-print server bioRxiv stated.

"We successfully isolated and characterized the SARS-CoV-2 from UK returnees in India with all signature mutations of the UK-variant," the document stated.

"We present the neutralizing antibodies (Nab) titers to underline the efficacy of Covaxin vaccine candidate against SARS-CoV-2 UK-variant and one of the heterologous strains. Sera collected from 38 vaccine recipients, who received Covaxin vaccine-candidate in phase-II trial had equivalent NAb titers to homologous strain and two heterologous strains with the characteristic substitution of the UK-variant," the study authors said.

"Our study evidently highlighted comparable neutralization activity of vaccinated individuals sera against variant as well as heterologous SARS-CoV-2 strains."

"Importantly, sera from the vaccine recipients could neutralise the UK-variant strains discounting the uncertainty around potential escape. It was reassuring from the neutralizing antibodies data generated in our laboratory that the indigenous Covaxin following its rollout in the vaccination program, could be expected to work against the new UK-variant. It is unlikely that the mutation would be able to dampen the potential benefits of the vaccine in concern," it said.